
ESMO 2019: Clinical benefit with first-line immunotherapy in advanced hepatocellular carcinoma
New data have shown a trend towards clinically meaningful improvements in survival and response rates…
New data have shown a trend towards clinically meaningful improvements in survival and response rates…